Effect of Night-time and Full-time Splinting for Carpal Tunnel Syndrome (FINCROSS)
Carpal Tunnel Syndrome
About this trial
This is an interventional treatment trial for Carpal Tunnel Syndrome focused on measuring carpal tunnel syndrome, splinting, no-treatment, cross-over trial
Eligibility Criteria
Inclusion Criteria: Clinically confirmed carpal tunnel syndrome (CTS) of any severity level (diagnostic criteria: numbness, pain or paraesthesia in the median nerve distribution area of wrist and fingers), Symptom duration of CTS for at least 3 weeks, No previous corticosteroid injection or surgery during last 6 months, Aged 18 years or older, Able to complete self-report questionnaires electronically, Able to understand Finnish, Willing to join the study and follow the study protocol instructions, Sign informed consent. Exclusion Criteria: Cervical radiculopathy, Other neurological condition affecting the function of the hand such as Multiple Sclerosis, previous nerve injury, Active Rheumatoid arthritis or any other active inflammatory joint disease affecting the hand, Thenar muscle atrophy, Hypothyroidism, Known allergy to any of the splint materials (self-reported by patient), Long term treatment (over 4 months) for CTS with no response, Any other known reason that could prevent from participation for the study time.
Sites / Locations
- Terveystalo KamppiRecruiting
- Hospital Nova of Central FinlandRecruiting
- Terveystalo JyväskyläRecruiting
- Tampere University Hospital
- Terveystalo TampereRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Other
Other
Other
Other
Other
Other
Sequence of three treatment periods in the following order: ABC
Sequence of three treatment periods in the following order: ACB
Sequence of three treatment periods in the following order: BAC
Sequence of three treatment periods in the following order: BCA
Sequence of three treatment periods in the following order: CAB
Sequence of three interventions/treatments in the following order: CBA
Splinting at night while sleeping for 6 weeks (period A), then no treatment for 6 weeks (period B), then splinting at day and night for 6 weeks (period C). Each treatment period will be separated by 3-week washout period.
Splinting at night while sleeping for 6 weeks (period A), then splinting at day and night for 6 weeks (period C), then no treatment for 6 weeks (period B). Each treatment period will be separated by 3-week washout period.
No treatment for 6 weeks (period B), then splinting at night while sleeping for 6 weeks (period A), then splinting at day and night for 6 weeks (period C). Each treatment period will be separated by 3-week washout period.
No treatment for 6 weeks (period B), then splinting at day and night for 6 weeks (period C), then splinting at night while sleeping for 6 weeks (period A). Each treatment period will be separated by 3-week washout period.
Splinting at day and night for 6 weeks (period C), then splinting at night while sleeping for 6 weeks (period A), then no treatment for 6 weeks (period B). Each treatment period will be separated by 3-week washout period.
Splinting at day and night for 6 weeks (period C), then no treatment for 6 weeks (period B), then splinting at night while sleeping for 6 weeks (period A). Each treatment period will be separated by 3-week washout period.